HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).

Abstract
54 consecutively referred, previously untreated patients with stage II and III multiple myeloma have been treated with the M-2 protocol. 50% of patients had a performance status of less than 50%. 13% were stage II and 87% stage III. In 50 of 54 patients (90%), and objective response according to the Myeloma Task Force was achieved; 10% of the responses have been complete (9+, 15+, 17+, 18+ and 66+ months). Remissions now range from 1 to 86+ months. The actuarial median survival determined from the initiation of therapy will exceed 4 years. Toxicity was acceptable with mild myelosuppression. These results confirm the efficacy of the M-2 protocol in multiple myeloma with regards to response rate and survival.
AuthorsD C Case Jr, H L Sonneborn, S D Paul, D M Hayes, B M Dorsk, R J Carroll, L Bove
JournalOncology (Oncology) Vol. 42 Issue 3 Pg. 137-40 ( 1985) ISSN: 0030-2414 [Print] SWITZERLAND
PMID3858763 (Publication Type: Journal Article)
Chemical References
  • Immunoglobulins
  • Myeloma Proteins
  • Vincristine
  • Cyclophosphamide
  • Melphalan
  • Carmustine
  • Prednisone
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Blood Urea Nitrogen
  • Carmustine (adverse effects, therapeutic use)
  • Cyclophosphamide (adverse effects, therapeutic use)
  • Humans
  • Immunoglobulins (analysis)
  • Leukemia, Monocytic, Acute (chemically induced)
  • Melphalan (adverse effects, therapeutic use)
  • Middle Aged
  • Multiple Myeloma (drug therapy)
  • Myeloma Proteins (analysis)
  • Prednisone (adverse effects, therapeutic use)
  • Prognosis
  • Time Factors
  • Vincristine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: